19:55 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Prothena discontinues development of psoriasis/psoriatic arthritis candidate

Prothena Corp. plc (NASDAQ:PRTA) said Phase Ib data for PRX003 do not support moving the psoriasis/psoriatic arthritis candidate into mid-stage development. PRX003 is a mAb targeting melanoma cell adhesion molecule (MCAM; MUC18; CD146). Data from the...
07:00 , Jun 25, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Connective tissue growth factor (CTGF); melanoma cell adhesion molecule (MCAM; MUC18; CD146)

Musculoskeletal disease INDICATION: Musculoskeletal disease In vitro and rat studies suggest CTGF could help regenerate tendon tissue after injury. In primary rat patellar tendon cells, CTGF selectively induced propagation of cells expressing the tendon stem cell marker...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

PRX003: Phase I started

Prothena began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV PRX003 in up to 40 healthy volunteers. Prothena expects to start a Phase I trial of multiple ascending doses...
07:00 , Aug 27, 2012 |  BioCentury  |  Strategy

Another cut at Elan

Elan Corp. plc says spinning out its drug discovery and preclinical assets will give investors a choice - a profitable Elan with a growing revenue stream from autoimmune drug Tysabri natalizumab, or a pure-play science...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Elan neurology, autoimmune news

Elan announced plans to retain its late stage and marketed assets and spin out its discovery and early stage programs into a public company called Neotope Biosciences plc. Elan said splitting the company would better...
00:37 , Aug 14, 2012 |  BC Extra  |  Top Story

Elan to spin out drug discovery

Elan Corp. plc (NYSE:ELN) announced plans to spin out its early stage drug development operations into a public company called Neotope Biosciences plc. Neotope will be incorporated in Ireland with operations in South San Francisco,...
07:00 , Apr 16, 2012 |  BioCentury  |  Product Development

CellSearching the heart

Eight years after launching CellSearch to identify and count circulating tumor cells, Johnson & Johnson's Veridex LLC unit has new data showing the technology may have the potential to predict heart attacks. Additional testing will...
08:00 , Mar 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia; reperfusion injury Not applicable In vitro and rat studies suggest that a soluble form of...
07:00 , May 1, 2008 |  BC Innovations  |  Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Modeling cell-surface behavior of glycopolymers ...
08:00 , Jan 14, 2002 |  BC Week In Review  |  Clinical News

ABX-MA1: ABGX submitted an IND to begin this quarter a U.S. Phase I trial in 15-30 patients with metastatic melanoma.

Abgenix Inc. (ABGX), Fremont, Calif.   Product: ABX-MA1   Business: Cancer   Therapeutic category: Angiogenesis, Antibody   Target: MUC18 adhesion molecule   Description: Humanized monoclonal antibody against MUC18   Indication: Treat metastatic melanoma   Endpoint: Safety   Status: ABGX submitted an...